Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT versus conservative treatment for focal knee cartilage lesions
NL-OMON59866Phase 3Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2024
- Modality
- Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous cultured chondrocytes and Provacel in cartilage defect (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Clinical improvement by KOOS at 9 months and Quality of life by EQ-5D at 9 months. Started Dec 2024; status: completed.
02
Drugs
autologous cultured chondrocytesProvacel
03
Conditions
cartilage defect
Beyond the preview
Go deeper on NL-OMON59866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59866.